SCHEMBL13908363

SCHEMBL13908363

COC(=O)[C@H](C)N(Cc1ccccc1)C(=O)[C@H](C)N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ ANPEP P15144 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ MMP1 P03956 1/20 0.40
▸ MMP3 P08254 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27759421 1.00 KMT2A (0.51) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL30295062 0.92 KMT2A (0.47) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL23058774 0.88 MEN1 (0.48) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL23039954 0.88 MEN1 (0.48) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL23039956 0.88 MEN1 (0.48) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL13733686 0.88 MEN1 (0.48) KMT2AMEN1L3MBTL1LMNAALDH1A1
Hydrochloric Acid SCHEMBL13733682 0.87 MEN1 (0.47) KMT2AMEN1L3MBTL1LMNAALDH1A1
Hydrochloric Acid SCHEMBL13733690 0.87 MEN1 (0.47) KMT2AMEN1L3MBTL1LMNAALDH1A1
Hydrochloric Acid SCHEMBL30521710 0.87 MEN1 (0.47) KMT2AMEN1L3MBTL1LMNAALDH1A1
SCHEMBL23058787 0.85 MEN1 (0.46) KMT2AMEN1L3MBTL1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101404987-A Use of sulfonamide derivatives for the treatment of disorders of the surrogate and nervous systems SMITHKLINE BEECHAM CORP (US) 2009-04-08 — — CN disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A KMT2A 3729/4885MEN1 2095/4885L3MBTL1 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback